Edward F. Attiyeh, MD

Attending physician

Assistant professor of Pediatrics, University of Pennsylvania School of Medicine

Contact Edward F. Attiyeh, MD



This email address is being protected from spambots. You need JavaScript enabled to view it.


Children's Hospital of Philadelphia 3501 Civic Center Blvd., CTRB 3050
(267) 426-5534



Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine (2007– present)


M.D., Albert Einstein College of Medicine (1999)
A.B., Molecular Biology, Princeton University (1995)
Specialties and Services: Oncology


Albert Einstein College of Medicine, New York, NY
AB, Princeton University (Molecular Biology), Princeton, NJ


Resident in Pediatrics, Yale-New Haven Children's Hospital, New Haven, Conn.


Fellow in Pediatric Hematology/Oncology, Children's Hospital of Philadelphia, Philadelphia, Pa.

Board Certification

American Board of Pediatrics (2002)
American Board of Pediatrics/Hematology-Oncology (2006)

Year Appointed


Extended Bio

I see general oncology patients and patients with rare liver cancer. My clinical focus is tied to my research in neuroblastoma.

Neuroblastoma is the pediatric cancer whose genetics we know most about. Many neuroblastoma patients do well, but others have a very aggressive form of the disease. But until now, the tools for determining who's at greatest risk of relapse haven't been precise. We need to find genetic markers that could help identify the patients who could potentially benefit from more intensive therapy. Finding the genes involved in aggressive neuroblastoma also will help us develop targeted therapeutic agents.

My colleagues and I are looking at the biology of the neuroblastoma cell – the critical cell pathways that will help us identify how to better treat the disease and prevent relapse. Our goal is to understand what can interrupt and treat the disease: what genes and changes in the neuroblastoma cell explain why they became a cancer.

The genetics of cancer has long been an interest of mine. As I progressed through my medical education, the concept of cancer being a disease of the genome (DNA) became more and more apparent to me. I realized there were genes that control how fast cells grow and when they stop growing. I saw how this connected with medicine -- and found I wanted to unite my clinical and scientific interests in the study of genomics.

Our clinical research at Children's Hospital focuses on critical changes in the genome and the specific chromosomes associated with the worst patient neuroblastoma outcomes. Using microarrays DNA technology, we are trying to understand how cells change. Next, we will be able to move beyond learning about a single gene to sequencing the entire genome.

Our goal is to identify certain cell subtypes within neuroblastoma. Every child's cancer is different, but understanding the subtypes means we can better target the individual cancer cell abnormality and tailor the therapy to each individual patient. More specifically, our genome work involves analysis of tissue samples from children with neuroblastoma to determine the relationship between disease progression and an abnormal deletion in the "q" arm of chromosome 11. We found that patients with chromosome 11q and chromosome 1p deletion are more likely to have aggressive neuroblastoma. Identifying these genetic markers is helping us better design therapies to potentially improve patient survival.

When it comes to caring for our patients with neuroblastoma and other pediatric cancers, my approach with patients and families has always been to make the child the focus of the care. I help the child communicate what he or she is experiencing. And since there is a lot of uncertainly revolving around cancer treatment, I try to anticipate what our patients and their families are thinking -- and let them know the possibilities and status of their situation.

One of the most attractive things about working in oncology at Children's Hospital, along with our top clinicians and researchers, is the broader staff involved. The nurses, social worker and psychologists are all specifically dedicated to work with our special cancer population.


Selected Publications

Pugh Trevor J, Morozova Olena, Attiyeh Edward F, Asgharzadeh Shahab, Wei Jun S, Auclair Daniel, Carter Scott L, Cibulskis Kristian, Hanna Megan, Kiezun Adam, Kim Jaegil, Lawrence Michael S, Lichenstein Lee, McKenna Aaron, Pedamallu Chandra Sekhar, Ramos Alex H, Shefler Erica, Sivachenko Andrey, Sougnez Carrie, Stewart Chip, Ally Adrian, Birol Inanc, Chiu Readman, Corbett Richard D, Hirst Martin, Jackman Shaun D, Kamoh Baljit, Khodabakshi Alireza Hadj, Krzywinski Martin, Lo Allan, Moore Richard A, Mungall Karen L, Qian Jenny, Tam Angela, Thiessen Nina, Zhao Yongjun, Cole Kristina A, Diamond Maura, Diskin Sharon J, Mosse Yael P, Wood Andrew C, Ji Lingyun, Sposto Richard, Badgett Thomas, London Wendy B, Moyer Yvonne, Gastier-Foster Julie M, Smith Malcolm A, Auvil Jaime M Guidry, Gerhard Daniela S, Hogarty Michael D, Jones Steven J M, Lander Eric S, Gabriel Stacey B, Getz Gad, Seeger Robert C, Khan Javed, Marra Marco A, Meyerson Matthew, Maris John M. The genetic landscape of high-risk neuroblastoma.. Nature genetics. Vol 45(3) . 2013 Mar:279-84.
Chand Damini, Yamazaki Yasuo, Ruuth Kristina, Schönherr Christina, Martinsson Tommy, Kogner Per, Attiyeh Edward F, Maris John, Morozova Olena, Marra Marco A, Ohira Miki, Nakagawara Akira, Sandström Per-Erik, Palmer Ruth H, Hallberg Bengt. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.. Disease models & mechanisms. Vol 6(2) . 2013 Mar:373-82.
Diskin Sharon J, Capasso Mario, Schnepp Robert W, Cole Kristina A, Attiyeh Edward F, Hou Cuiping, Diamond Maura, Carpenter Erica L, Winter Cynthia, Lee Hanna, Jagannathan Jayanti, Latorre Valeria, Iolascon Achille, Hakonarson Hakon, Devoto Marcella, Maris John M. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.. Nature genetics. 2012 Sep.
Schleiermacher G, Mosseri V, London W B, Maris J M, Brodeur G M, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini G P, Fischer M, Ambros I, Monclair T, Matthay K K, Ambros P, Cohn S L, Pearson A D J. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.. British journal of cancer. 2012 Sep.
Bosse Kristopher R, Diskin Sharon J, Cole Kristina A, Wood Andrew C, Schnepp Robert W, Norris Geoffrey, Nguyen Le B, Jagannathan Jayanti, Laquaglia Michael, Winter Cynthia, Diamond Maura, Hou Cuiping, Attiyeh Edward F, Mosse Yael P, Pineros Vanessa, Dizin Eva, Zhang Yongqiang, Asgharzadeh Shahab, Seeger Robert C, Capasso Mario, Pawel Bruce R, Devoto Marcella, Hakonarson Hakon, Rappaport Eric F, Irminger-Finger Irmgard, Maris John M. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.. Cancer research. Vol 72(8) . 2012 Apr:2068-78.
Gumy-Pause Fabienne, Pardo Bruno, Khoshbeen-Boudal Mary, Ansari Marc, Gayet-Ageron Angèle, Sappino André-Pascal, Attiyeh Edward F, Ozsahin Hulya. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.. Genes, chromosomes & cancer. Vol 51(2) . 2012 Feb:174-85.
Dondeti Vijay R, Wubbenhorst Bradley, Lal Priti, Gordan John D, D'Andrea Kurt, Attiyeh Edward F, Simon M Celeste, Nathanson Katherine L. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets.. Cancer research. Vol 72(1) . 2012 Jan:112-21.
Dubois Steven G, Geier Ethan, Batra Vandana, Yee Sook Wah, Neuhaus John, Segal Mark, Martinez Daniel, Pawel Bruce, Yanik Greg, Naranjo Arlene, London Wendy B, Kreissman Susan, Baker David, Attiyeh Edward, Hogarty Michael D, Maris John M, Giacomini Kathleen, Matthay Katherine K. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.. International journal of molecular imaging. Vol 2012. 2012:250834.
Nguy?n L? B, Diskin Sharon J, Capasso Mario, Wang Kai, Diamond Maura A, Glessner Joseph, Kim Cecilia, Attiyeh Edward F, Mosse Yael P, Cole Kristina, Iolascon Achille, Devoto Marcella, Hakonarson Hakon, Li Hongzhe K, Maris John M. Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci.. PLoS genetics. Vol 7(3) . 2011 Mar:e1002026.
Cole Kristina A, Huggins Jonathan, Laquaglia Michael, Hulderman Chase E, Russell Mike R, Bosse Kristopher, Diskin Sharon J, Attiyeh Edward F, Sennett Rachel, Norris Geoffrey, Laudenslager Marci, Wood Andrew C, Mayes Patrick A, Jagannathan Jayanti, Winter Cynthia, Mosse Yael P, Maris John M. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.. Proceedings of the National Academy of Sciences of the United States of America. Vol 108(8) . 2011 Feb:3336-41.


Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2009; 52(1): 44-50.

Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009 Jun; 459(7249): 987-91.

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nature Genetics. 2009 Jun; 41(6): 718-723.

Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, et al. Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer research. 2009 May; 69(10): 4143-9.

Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. British Journal of Haematology. 2009 Apr; 145(1): 101-6.

Attiyeh EF, Diskin SJ, Attiyeh MA, Mossé YP, Hou C, Jackson EM, et al. Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome research. 2009 Feb; 19(2): 276-83.

Winter C, Pawel B, Seiser E, Zhao H, Raabe E, Wang Q, et al. Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. Pediatr Blood Cancer. 2008; 51(1): 10-6.

Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215): 930-5.

Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008; 358(24): 2585-93.

Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008; 6(5): 735-42.

Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes, Chromosomes and Cancer. 2007 Oct; 46(10): 936-49.

George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. Public Library of Science. 2007 Feb; ONE 2: e255.